EGFR and cancer: These results act in concert with the study of Tuccillo et al. [37], who examined the additive effect of the anti-cancer drug-combination of ZD6474 (a EGFR and VEGFR inhibitor) and SC-236 (a selective COX-2 inhibitor) on the xenograft models of lung and colon cancer, and these results are also in agreement with the study of Mann et al. [33] and Tortora et al. [34].